Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18944516 | BACILLUS STRAINS FOR IMPROVING FEED CONVERSION RATES AND BODY WEIGHT GAIN IN ANIMALS | November 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18787340 | LIVE TESTS FOR DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY IN ANIMALS AND HUMANS | July 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18763332 | MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONS | July 2024 | March 2025 | Allow | 8 | 0 | 0 | No | No |
| 18741232 | PURIFIED CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE | June 2024 | June 2025 | Allow | 12 | 1 | 0 | No | No |
| 18734806 | OMPG VARIANTS | June 2024 | June 2025 | Allow | 12 | 0 | 0 | Yes | No |
| 18665018 | MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETO | May 2024 | February 2025 | Allow | 9 | 0 | 0 | No | No |
| 18662515 | MICROBIOME RELATED IMMUNOTHERAPIES | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18660419 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18637589 | METHODS FOR PRODUCING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CARRIER PROTEIN CONJUGATES | April 2024 | May 2025 | Allow | 13 | 2 | 0 | No | No |
| 18633691 | LONG LASTING EFFECT OF NEW BOTULINUM TOXIN FORMULATIONS | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18599359 | ANTIBODIES AGAINST MICROORGANISMS AND USES THEREOF | March 2024 | June 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18442506 | CATTLE FEVER TICK-INFESTATION VACCINES AND USES THEREOF | February 2024 | February 2025 | Allow | 12 | 1 | 0 | No | No |
| 18440212 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES | February 2024 | May 2025 | Allow | 15 | 1 | 0 | No | No |
| 18424354 | SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | January 2024 | May 2025 | Allow | 15 | 1 | 1 | No | No |
| 18409857 | GUT MICROBES AGAINST INFECTIOUS DISEASES AND ITS USE | January 2024 | February 2025 | Allow | 13 | 1 | 1 | No | No |
| 18544698 | SLAM POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF | December 2023 | January 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18533453 | PROBIOTIC BACTERIAL STRAINS PRODUCING ANTIMICROBIAL PROTEINS AND COMPOSITIONS COMPRISING THESE FOR USE IN THE TREATMENT OF DIARRHEAL AND OTHER MICROBIAL DISEASES | December 2023 | January 2025 | Abandon | 13 | 0 | 1 | No | No |
| 18532731 | INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRO | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18501825 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | November 2023 | October 2024 | Allow | 11 | 2 | 2 | No | No |
| 18493396 | Bacteriophage Composition And Method of Preventing Bacterial Infections in Livestock | October 2023 | November 2024 | Allow | 13 | 1 | 0 | No | No |
| 18487437 | COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND ANOTHER BIOLOGICAL CONTROL AGENT | October 2023 | November 2024 | Allow | 13 | 1 | 1 | No | No |
| 18378736 | SYSTEM, METHOD, APPARATUS AND DIAGNOSTIC TEST FOR PLASMODIUM VIVAX | October 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18485268 | BACILLUS STRAINS FOR IMPROVING FEED CONVERSION RATES AND BODY WEIGHT GAIN IN ANIMALS | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18464051 | ANTIGENS FOR DETECTING TOXOPLASMA INFECTION BY MONITORING CELLULAR IMMUNITY | September 2023 | August 2024 | Allow | 11 | 1 | 0 | No | No |
| 18451461 | COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI | August 2023 | June 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18449904 | OMPG VARIANTS | August 2023 | March 2024 | Allow | 7 | 0 | 0 | No | No |
| 18350267 | BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF | July 2023 | March 2025 | Allow | 21 | 2 | 0 | No | No |
| 18344780 | IMMUNOGENICITY OF A CPG-ADJUVANTED RECOMBINANT PLAGUE VACCINE | June 2023 | March 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18343944 | MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF FIBROSIS | June 2023 | December 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 18338961 | GLYCOCONJUGATION PROCESSES AND COMPOSITIONS | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18335489 | ANTI-LAM AND ANTI-PIM6/LAM MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18335717 | GENETICALLY MODIFIED HAPLOID ISSATCHENKIA ORIENTALIS | June 2023 | September 2024 | Allow | 15 | 2 | 0 | No | No |
| 18331298 | Combinations of Yersinia Entomophaga and Pesticides or Other Substances | June 2023 | April 2024 | Allow | 11 | 1 | 0 | No | No |
| 18203917 | PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING PASTEURELLA PROTEINS AND METHODS OF USE | May 2023 | October 2024 | Allow | 17 | 2 | 1 | No | No |
| 18318909 | SOUTHERN CATTLE TICK VACCINE PRODUCT | May 2023 | April 2024 | Allow | 11 | 2 | 0 | No | No |
| 18316499 | Attenuating bacterial virulence by attenuating bacterial folate transport | May 2023 | February 2024 | Allow | 9 | 0 | 0 | No | No |
| 18144568 | POLYPEPTIDES OF FUSOBACTERIUM AND METHODS OF USE | May 2023 | August 2024 | Allow | 15 | 2 | 1 | No | No |
| 18309555 | COMPOSITIONS FOR USE AS A PROPHYLACTIC AGENT TO THOSE AT RISK OF INFECTION OF TUBERCULOSIS, OR AS SECONDARY AGENTS FOR TREATING INFECTED TUBERCULOSIS PATIENTS | April 2023 | July 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18188969 | COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF | March 2023 | February 2024 | Allow | 10 | 0 | 0 | No | No |
| 18188987 | COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF | March 2023 | August 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18026904 | MICROORGANISM STRAIN PEDIOCOCCUS ACIDILACTICI TAK 589 COCCOBEST AS AN ANTIMICROBIAL AND ANTIOXIDANT PROBIOTIC | March 2023 | June 2025 | Allow | 27 | 0 | 0 | No | No |
| 18159718 | MUTANT PORES | January 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18155301 | LONG LASTING EFFECT OF NEW BOTULINUM TOXIN FORMULATIONS | January 2023 | December 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 18154642 | VACCINE FOR FALCIPARUM MALARIA | January 2023 | August 2024 | Allow | 20 | 2 | 0 | No | No |
| 18088690 | BURKHOLDERIA PSEUDOMALLEI COMPLEX OUTER MEMBRANE VESICLES AS ADJUVANTS | December 2022 | October 2023 | Allow | 10 | 2 | 0 | No | No |
| 18145411 | METHOD OF PRODUCING STREPTOCOCCUS THERMOPHILUS MUTANT STRAINS | December 2022 | March 2023 | Allow | 3 | 0 | 0 | No | No |
| 18062934 | MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITION AND METHODS OF MANUFACTURE | December 2022 | January 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18060401 | TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE | November 2022 | September 2024 | Allow | 21 | 3 | 1 | Yes | No |
| 17923853 | SHIGELLA-BASED MINIMAL PLASMID RECOMBINANT INVASION CONSTRUCT | November 2022 | April 2025 | Allow | 29 | 0 | 0 | No | No |
| 18052434 | CHIMERIC M. HYORHINIS POLYPROTEIN FOR VACCINES AND DIAGNOSTICS | November 2022 | September 2023 | Allow | 11 | 2 | 0 | No | No |
| 18052038 | CATTLE FEVER TICK-INFESTATION VACCINES AND USES THEREOF | November 2022 | November 2023 | Allow | 12 | 1 | 1 | Yes | No |
| 18049507 | METHODS FOR PRODUCING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CARRIER PROTEIN CONJUGATES | October 2022 | January 2024 | Allow | 15 | 2 | 1 | No | No |
| 18047395 | MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS | October 2022 | May 2024 | Allow | 19 | 2 | 0 | No | No |
| 17938184 | Synergistic Bacterial Compositions and Methods of Production and Use Thereof | October 2022 | April 2024 | Allow | 19 | 1 | 1 | No | No |
| 17953712 | MALARIA IMMUNOGEN AND METHODS FOR USING SAME | September 2022 | June 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17933952 | Method for Diagnostics, Treatment and Prevention of Parkinson's Disease | September 2022 | October 2023 | Allow | 13 | 1 | 0 | Yes | No |
| 17933516 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES | September 2022 | March 2023 | Allow | 6 | 0 | 1 | No | No |
| 17933582 | MANAGEMENT OF PATHOGENIC LAWSONIA | September 2022 | July 2023 | Allow | 10 | 1 | 0 | No | No |
| 17888916 | POLYPEPTIDES OF FUSOBACTERIUM AND METHODS OF USE | August 2022 | August 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17885784 | IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF | August 2022 | February 2023 | Allow | 7 | 0 | 0 | No | No |
| 17885446 | PROBIOTIC FORMULATIONS AND METHODS FOR USE | August 2022 | January 2025 | Abandon | 29 | 2 | 0 | No | No |
| 17817113 | PROTISTS ENRICHED WITH LIPIDS RICH IN POLYUNSATURATED FATTY ACIDS | August 2022 | September 2024 | Allow | 25 | 1 | 1 | No | No |
| 17817272 | BORDETELLA STRAINS EXPRESSING SEROTYPE 3 FIMBRIAE | August 2022 | May 2025 | Allow | 33 | 1 | 0 | No | No |
| 17814281 | STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND CONJUGATES THEREOF | July 2022 | February 2025 | Allow | 31 | 0 | 0 | No | No |
| 17813065 | COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND ANOTHER BIOLOGICAL CONTROL AGENT | July 2022 | June 2023 | Allow | 11 | 0 | 1 | Yes | No |
| 17852211 | Animal Protein-Free Pharmaceutical Compositions | June 2022 | October 2022 | Allow | 4 | 2 | 0 | Yes | No |
| 17808678 | COMPOSITION COMPRISING NEW LACTOBACILLUS SALIVARIUS STRAINS AND METHOD FOR THE PREVENTION AND TREATMENT OF OTITIS AND UPPER RESPIRATORY INFECTIONS | June 2022 | November 2023 | Allow | 16 | 2 | 0 | No | No |
| 17829033 | VIRULENT AEROMONAS VACCINES AND METHODS | May 2022 | January 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17826617 | VACCINES AGAINST MALARIA TRANSMISSION | May 2022 | June 2023 | Allow | 13 | 1 | 2 | Yes | No |
| 17824378 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA OR LIMITING EIMERIA INFECTION | May 2022 | October 2023 | Allow | 17 | 1 | 1 | No | No |
| 17752277 | METHOD AND A SOLID SUPPORT FOR DETECTING TICK-BORNE MICROBES IN A BIOLOGICAL SAMPLE | May 2022 | January 2023 | Allow | 8 | 0 | 0 | Yes | No |
| 17742023 | ANTIGENS FOR DETECTING TOXOPLASMA INFECTION BY MONITORING CELLULAR IMMUNITY | May 2022 | November 2023 | Abandon | 18 | 1 | 1 | No | No |
| 17728483 | ANTI HLA-G SPECIFIC ANTIBODIES | April 2022 | December 2022 | Allow | 7 | 1 | 1 | No | No |
| 17723123 | ACETIC ACID BACTERIA-CONTAINING COMPOSITION | April 2022 | June 2025 | Allow | 38 | 1 | 1 | No | No |
| 17659466 | Compositions and methods for treating and preventing staphylococcus aureus infections | April 2022 | May 2023 | Allow | 13 | 1 | 0 | No | No |
| 17719674 | MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONS | April 2022 | April 2024 | Allow | 24 | 1 | 1 | No | No |
| 17714205 | Probiotic Immunomodulatory Compositions | April 2022 | March 2023 | Allow | 11 | 1 | 0 | No | No |
| 17705461 | COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI | March 2022 | May 2023 | Allow | 14 | 1 | 0 | No | No |
| 17764371 | THE COMPOSITION OF CULTURE MEDIA FOR FAECALIBACTERIUM PRAUSNITZII | March 2022 | February 2025 | Allow | 35 | 1 | 0 | No | No |
| 17698645 | OPTIMIZED CROSSLINKERS FOR TRAPPING A TARGET ON A SUBSTRATE | March 2022 | April 2024 | Allow | 25 | 1 | 0 | No | No |
| 17638528 | STRAIN HAVING ABILITY TO LOWER BLOOD AMMONIA LEVELS AND COMPOSITION COMPRISING SAME FOR NEURONAL PROTECTION | March 2022 | February 2025 | Allow | 36 | 1 | 1 | No | No |
| 17687313 | MODIFIED BRUCELLA VACCINE STRAIN FOR THE TREATMENT OF BRUCELLOSIS | March 2022 | March 2023 | Allow | 12 | 1 | 0 | No | No |
| 17684018 | BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF | March 2022 | May 2023 | Allow | 14 | 0 | 1 | No | No |
| 17679243 | COMPOSITIONS COMPRISING OF BACTERIAL STRAINS | February 2022 | May 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17651523 | NOVEL ANTI-LAM AND ANTI-PIM6/LAM MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS | February 2022 | March 2023 | Allow | 12 | 2 | 0 | No | No |
| 17633105 | COMPOSITIONS AND METHODS OF TREATING PSORIASIS AND ATOPIC DERMATITIS USING PREVOTELLA HISTICOLA | February 2022 | January 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17588760 | METHODS OF USING MONOCLONAL ANTIBODIES TARGETING EPITOPES OF ASPH | January 2022 | June 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17586968 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | January 2022 | January 2023 | Abandon | 11 | 1 | 0 | No | No |
| 17588122 | SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | January 2022 | October 2023 | Allow | 21 | 1 | 1 | No | No |
| 17628640 | MALARIA IMMUNOGEN AND METHODS FOR USING SAME | January 2022 | July 2024 | Allow | 30 | 0 | 0 | Yes | No |
| 17578537 | Application of breast milk-derived Lactobacillus reuteri in regulating maternal and infant immune function | January 2022 | September 2024 | Allow | 32 | 1 | 0 | No | No |
| 17626628 | COMPOSITION AND METHOD FOR PREVENTING, ALLEVIATING, OR TREATING LIVER INJURY | January 2022 | February 2025 | Allow | 37 | 2 | 1 | No | No |
| 17625715 | ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMS | January 2022 | September 2024 | Allow | 32 | 0 | 1 | No | No |
| 17622546 | OLFACTORY RECEPTOR AS MICROGLIA MARKER AND USE THEREOF | December 2021 | January 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17556294 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING AUTOIMMUNE DISEASES | December 2021 | May 2025 | Allow | 41 | 2 | 1 | No | No |
| 17596652 | ANTIBODY-MEDIATED NEUTRALIZATION OF BETA-LACTAMASES | December 2021 | April 2025 | Allow | 40 | 1 | 1 | No | No |
| 17644019 | VACCINES | December 2021 | December 2023 | Allow | 24 | 1 | 1 | No | No |
| 17618582 | PROBIOTIC AND CHEMICAL CONTROL OF BIOFILMS | December 2021 | December 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17549845 | METHODS OF PRODUCING AGGREGATE-FREE MONOMERIC DIPHTHERIA TOXIN FUSION PROTEINS AND THERAPEUTIC USES | December 2021 | December 2023 | Allow | 24 | 1 | 1 | No | No |
| 17617802 | DETECTION OF ANTIGENS | December 2021 | March 2025 | Allow | 39 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GRASER, JENNIFER E.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GRASER, JENNIFER E works in Art Unit 1645 and has examined 1,313 patent applications in our dataset. With an allowance rate of 73.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner GRASER, JENNIFER E's allowance rate of 73.2% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by GRASER, JENNIFER E receive 1.51 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GRASER, JENNIFER E is 25 months. This places the examiner in the 65% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +27.0% benefit to allowance rate for applications examined by GRASER, JENNIFER E. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 35.5% of applications are subsequently allowed. This success rate is in the 75% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 86.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 75.7% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 12.1% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.